StockData
Relay Therapeutics, Inc. logo

Relay Therapeutics, Inc. (RLAY) stock

RLAYNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/30
$16.51+0.04 (+0.24%)

Close on Nov 18, 2026Market cap $3.62BP/E –Yield –

Relay Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Relay Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $10.35M, up 23.9% year over year. For fiscal 2025 it was $15.36M, up 53.4% from the year before. The highest annual figure on record is $82.65M in fiscal 2020.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$15.36M+53.4%
FY2024Dec 31, 2024$10.01M-60.8%
FY2023Dec 31, 2023$25.55M+1749.8%
FY2022Dec 31, 2022$1.38M-54.4%
FY2021Dec 31, 2021$3.03M-96.3%
FY2020Dec 31, 2020$82.65M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$350.00K-48.3%
Q1 FY2026Mar 31, 2026$3.00M-60.9%
Q4 FY2025Dec 31, 2025$7.00M–
Q3 FY2025Sep 30, 2025$0–
Q2 FY2025Jun 30, 2025$677.00K–
Q1 FY2025Mar 31, 2025$7.68M-23.3%
Q4 FY2024Dec 31, 2024$0-100.0%
Q3 FY2024Sep 30, 2024$0-100.0%
Q2 FY2024Jun 30, 2024$0-100.0%
Q1 FY2024Mar 31, 2024$10.01M+3855.3%
Q3 FY2023Sep 30, 2023$25.20M+7226.2%
Q2 FY2023Jun 30, 2023$119.00K-67.4%
Q1 FY2023Mar 31, 2023$226.00K-46.1%
Q4 FY2022Dec 31, 2022$253.00K-55.4%
Q3 FY2022Sep 30, 2022$344.00K-48.3%
Q2 FY2022Jun 30, 2022$365.00K-56.8%
Q1 FY2022Mar 31, 2022$419.00K-56.0%
Q4 FY2021Dec 31, 2021$567.00K–
Q3 FY2021Sep 30, 2021$666.00K–
Q2 FY2021Jun 30, 2021$844.00K–
Q1 FY2021Mar 31, 2021$952.00K–

More Relay Therapeutics figures

See a number that looks wrong?